Abstract:Abstract Background Triple-negative breast cancer (TNBC) contributes to poor prognosis and there is no established standard chemotherapy this subtype of patients. It has been postulated that related cancers would confer sensitivity to certain cytotoxic agents like cisplatin. Cisplatin and gemcitabine have single-agent activity in metastatic breast cancer and preclinical data support synergy of the combination. The objective of this study was to evaluate doublet with gemcitabine/Cisplatin (GP) as first-line therapy in patients with metastatic TNBC. Material and Methods: This is a prospective single-institutional, open-label, phase II trial. The primary endpoint was progression free survival (PFS). Eligible subjects were aging from 18 to 75 years old, with no prior chemotherpay for MBC, with tumors negative for ER, PR or HER2, with at least one measurable disease according to the RECIST criteria, with ECOG PS of 0–1, and with adequate organ function. All patients received 21-day cycles of gemcitabine 1,000mg/m2 on days 1 and 8 and cisplatin 25 mg/m2 on days 1 through 3. Treatment was continued until disease progression or unacceptable toxicity or up to 8 cycles. (ClinicalTrials.gov number, NCT00601159) Results: A median age was 49 years (range: 29–74 years). 58 patients had received neo/adjuvant chemotherapy (53 patients with anthracycline and/or taxane). The median number of treatment cycles was six (range: 2–8 cycles). In 64 assessable patients, we observed 10 complete response (CR; 15.6%), 30 partial responses (PR; 46.9%), 17 patients (26.6%) with stable disease (SD), and 7 patients (10.9%) with progressive disease, for an overall response rate of 62.5% (95% CI, 50.3% to 74.7%)..*** The median PFS was 7.7 months (95% CI, 6.0 to 9.4). With a median follow-up time of 28 months, the median overall survival was 19.1 months (95% CI, 12.5 to 25.7). Grade 3 or 4 toxicities were neutropenia 42.2%, thrombocytopenia 29.7%, anemia 18.8%, nausea/vomiting 15.6%, fatigue 14.1%, constipation 3%, sensory neuropathy 1.6%, 2 patients developed febrile neutropenia. The chemotherapy doses were reduced in 13.3% (6 pts) because of toxicity. There were no treatment-related deaths. Conclusion: Significant activity and favorable toxicity profile of GP regimen as first-line chemotherapy in patients with metastatic TNBC. It provided a basis for considering GP for further evaluation in phase III trials for women with metastatic TNBC in China. (ClinicalTrials. gov number, NCT01287624) Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-19-06.

Gemcitabine based combination regimens for treatment of refractory advanced breast cancer

A Meta-Analysis of Gemcitabine Containing Chemotherapy for Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Evaluation of Efficacy and Toxicity of Gemcitabine in Combination with Vinorelbine in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines and Taxanes

Clinical Observation of Gemcitabine Combined with Cisplatin As Second- or Third-Line on Patients with Advanced Triple-Negative Breast Cancer

The effect of Gemcitabine combined Capecitabine regimens for anthracycline-and taxane-refractory metastatic breast cancer

Clinical Research for Gemcitabine Combined with Fluorouracil in the Treatment of Advanced Ovarian Cancer Patients with Taxane and Cisplatin Resistance

Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review

Clinical value of gemcitabine plus cisplatin or capecitabine in the treatment of resistant advanced breast cancer

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer.

Gemcitabine Plus Cisplatin for the Treatment of Anthracycine-Resistant Advanced Breast Cancer

[Efficacy of Gemcitabine-Based Chemotherapy on Advanced Pancreatic Cancer].

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

A Study of Combination Chemotherapy with Gemcitabine(Gemzar) and Cisplatin for Patients with Advanced or Recurrent Cervical Cancer

Vinorelbine based combination chemotherapy in advanced non-small cell lung cancer

Gemcitabine Plus Oxaliplatin Combination in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Effect Observation of Gemcitabine Combined with Lobaplatin in Treatment of Relapsed Refractory Breast Cancer

Advanced Breast Angiosarcoma Completely Responding to Gemcitabine-Containing Chemotherapy

Mitomycin-C and cisplatin for advanced refractory breast cancer

P5-19-06: Highly Effective of Gemcitabine and Cisplatin (GP) As First-Line Combination Therapy in Patients with Triple-Negative Metastatic Breast Cancer: Final Report of a Phase II Trial.

Gemcitabine Alone or in Combination with Cisplatin for Advanced Biliary Tract Carcinomas: an Overview of Clinical Evidence.